You are here: Industry Insights > TCR

News List

Neogene Therapeutics signs global license agreement with NCI for cancer treatment drugs.com
January 12, 2022
Biotechnology firm Neogene Therapeutics has signed an exclusive, global license agreement with the National Cancer Institute (NCI) for a portfolio...
BioNTech Acquires Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Maryland americanpharmaceuticalreview
August 05, 2021
BioNTech SE and Kite, a Gilead Company announced the closing of the acquisition of the solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility’s assets and leases in Gaithersburg, MD, from Kite.
BioNTech to Acquire Kite’s TCR Cell Therapy Platform and Mfg. Facility contractpharma
July 20, 2021
BioNTech SE and Kite, a Gilead Company, have entered a purchase agreement for BioNTech to acquire Kite’s solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD.
Selexis, KBI Biopharma, Immatics Partner to Advance TCR Program contractpharma
July 01, 2021
Selexis SA and KBI Biopharma, both JSR Life Sciences companies, have signed service agreements with Immatics N.V., a clinical-stage biopharmaceutical company focused on T cell redirecting cancer immunotherapies.
'Own' immune cells to target infectious diseases including COVID-19 worldpharmanews
April 26, 2020
The engineering of specific virus-targeting receptors onto a patient's own immune cells is now being explored by scientists from Duke-NUS Medical School (Duke-NUS).
Novartis, TScan collaborate to develop TCR therapies for solid tumours pharmaceutical-business-review
April 20, 2020
Novartis has collaborated with TScan Therapeutics for the discovery and development of T cell receptor (TCR) therapies to treat solid tumours.
GSK, Immatics team up for cancer cell therapies pharmatimes
March 10, 2020
Immatics Biotechnologies has announced a new strategic collaboration with GlaxoSmithKline (GSK), in order to develop novel adoptive cell therapies targeting multiple cancer indications.
Astellas, Adaptimmune to Co-Develop, Commercialize CAR-T and TCR T-Cell Therapies americanpharmaceuticalreview
January 19, 2020
Astellas Pharma, through its wholly-owned subsidiary Universal Cells, and Adaptimmune Therapeutics have entered into a co-development and co-commercialization agreement to bring new stem-cell derived allogeneic T-cell therapies to people with cancer.
Roivant and Sinovant launch biopharma firm Cytovant Sciences pharmaceutical-technology
April 09, 2019
Roivant and Sinovant launch biopharma firm Cytovant Sciences
Gritstone ramps up bispecifics with new antibody therapeutics chief fiercebiotech
December 28, 2018
Gritstone Oncology has appointed Jonah Rainey, Ph.D., to head up its bispecific antibody program as it moves into lead optimization.....

Previous page 1 2 Next page